Literature DB >> 7847294

Antimitochondrial antibody-negative primary biliary cirrhosis.

M A Lacerda1, J Ludwig, E R Dickson, R A Jorgensen, K D Lindor.   

Abstract

OBJECTIVES: We reviewed our experience with patients who had biochemical and histological features of primary biliary cirrhosis in the absence of antimitochondrial antibodies (AMA) to better understand this variant of the syndrome.
METHODS: During the period between 1976 to 1992, 597 patients with clinical and histological features of primary biliary cirrhosis were seen at the Mayo Clinic. Thirty-five (5.8%) of these patients were negative for antimitochondrial antibody and had normal cholangiographic studies. The records of these patients were reviewed for this study.
RESULTS: No difference was found between the two groups with respect to age, gender, or biochemical features. IgM and gamma-globulin levels were higher in the antimitochondrial antibody-positive than the antimitochondrial antibody-negative patients. What is more important, 96% of the AMA-negative patients who could be tested were positive for antinuclear antibody or anti-smooth-muscle antibodies. These tests were positive in only 56% of the antimitochondrial antibody-positive group (p < 0.05). The response of five of these patients to ursodeoxycholic acid appeared comparable to the response seen in antimitochondrial antibody-positive patients.
CONCLUSIONS: Patients with histological features of primary biliary cirrhosis, whether antimitochondrial antibody positive or negative, are quite comparable with respect to clinical and biochemical features. Other autoantibodies, such as antinuclear or anti-smooth-muscle antibodies, are more common in the antimitochondrial antibody-negative group. These two conditions might be part of a spectrum that has been termed "autoimmune cholangitis" and that is characterized by chronic cholestasis, histological features of chronic nonsuppurative destructive cholangitis, and the presence of any of a variety of serum autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7847294

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  28 in total

Review 1.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

Review 2.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 3.  Variant forms of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

4.  Answers to multiple choice questions.

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-12

5.  Histologic features of steatohepatitis in patients with a clinical diagnosis of autoimmune cholestasis.

Authors:  Diego Sánchez-Muñoz; Victor M Castellano-Megías; Manuel Romero-Gómez
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

6.  Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.

Authors:  P Invernizzi; P M Battezzati; A Crosignani; P Zermiani; M Bignotto; N Del Papa; M Zuin; M Podda
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 7.  Treatment of autoimmune cholangitis.

Authors:  L Mohr; T Heintges; F Hensel; C Niederau; D Häussinger
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

Review 8.  [1997 gastroenterology update--II].

Authors:  W Fischbach; V Gross; J Schölmerich; C Ell; P Layer; W E Fleig
Journal:  Med Klin (Munich)       Date:  1998-03-15

9.  Autoimmune cholangitis.

Authors:  J Heathcote
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

10.  Characterization of M2 antibodies in asymptomatic Chinese population.

Authors:  Xiao-Hua Jiang; Ren-Qian Zhong; Xiao-Yun Fan; Yin Hu; Feng An; Jian-Wen Sun; Xian-Tao Kong
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.